[
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-1",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#definitiongeneral519001",
    "clean_content": "Definition / general\n\n* Rare malignant histiocytic neoplasm with morphologic and phenotypic features of interdigitating dendritic cells"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-2",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#essentialfeatures519002",
    "clean_content": "Essential features\n\n* Most often involves lymph nodes, less commonly extranodal sites ([Mod Pathol 2023;36:100268](37406859))* Characterized by epithelioid or spindled cells with diffuse expression of S100 and histiocytic markers, without expression of Langerhans cell markers (CD1a, langerin) ([Mod Pathol 2023;36:100268](37406859))* Usually displays an aggressive clinical course, especially when multifocal ([Ann Hematol 2019;98:2641](31741033), [Am J Hematol 2024;99:871](38409747))* May be primary or secondary (i.e., associated with another hematologic neoplasm such as B cell lymphoma) ([Mod Pathol 2023;36:100268](37406859))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-3",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#terminology519003",
    "clean_content": "Terminology\n\n* Also known as interdigitating dendritic cell tumor* Classified under histiocytic / dendritic cell neoplasms in the 2022 WHO Classification of Haematolymphoid Tumours and the International Consensus Classification ([Leukemia 2022;36:1703](35732831), [Blood 2022;140:1229](35653592))* Included as a subtype of malignant histiocytosis (M group) in the Histiocyte Society classification, along with histiocytic sarcoma and Langerhans cell sarcoma ([Blood 2016;127:2672](26966089))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-4",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#icdcoding519004",
    "clean_content": "ICD coding\n\n* ICD-10: [C96.4](https://www.icd10data.com/ICD10CM/Codes/C00-D49/C81-C96/C96-/C96.4) - sarcoma of dendritic cells (accessory cells)"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-5",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#epidemiology519005",
    "clean_content": "Epidemiology\n\n* Predominantly adults with median age of 58 years ([Ann Hematol 2019;98:2641](31741033))* Slight male predominance (M:F = ~2:1) ([Am J Hematol 2024;99:871](38409747), [Ann Hematol 2019;98:2641](31741033))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-6",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#sites519006",
    "clean_content": "Sites\n\n* Nodal (commonly cervical, axillary and mediastinal) and a wide variety of extranodal sites (skin, liver, gastrointestinal tract, lung, spleen, salivary glands, soft tissue, bone marrow) ([Am J Hematol 2024;99:871](38409747), [Ann Hematol 2019;98:2641](31741033))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-7",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#pathophysiology519007",
    "clean_content": "Pathophysiology\n\n* Majority of cases show MAPK pathway activation (see [Molecular / cytogenetics description](https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#interdigitatingreticulummolecular))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-8",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#etiology519008",
    "clean_content": "Etiology\n\n* Etiology remains unknown* Secondary (associated with a hematologic neoplasm) in 10 - 20% of cases, most commonly secondary to B cell lymphoma, also may occur following T cell lymphoma or myeloid neoplasm ([Mod Pathol 2023;36:100268](37406859), [Ann Hematol 2019;98:2641](31741033), [Crit Rev Oncol Hematol 2013;88:253](23755890))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-9",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#clinicalfeatures519010",
    "clean_content": "Clinical features\n\n* Variable clinical signs / symptoms depending on the extent of disease, ranging from an asymptomatic solitary mass to systemic symptoms based on organ(s) involved ([Am J Hematol 2024;99:871](38409747), [Ann Hematol 2019;98:2641](31741033))* B symptoms (fever, night sweats, unintentional weight loss) may be present"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-10",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#diagnosis519011",
    "clean_content": "Diagnosis\n\n* Morphologic evaluation supplemented by a panel of immunostains (diffuse S100 expression in conjunction with positive expression of at least 2 histiocytic lineage markers [i.e., CD4, CD68, CD163, PU.1]) is key to diagnosing IDCS* IDCS can demonstrate either a monocyte macrophage phenotype or a classical dendritic cell phenotype* Reference: [Mod Pathol 2023;36:100268](37406859)"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-11",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#prognosticfactors519015",
    "clean_content": "Prognostic factors\n\n* Multifocal / disseminated disease with risk of organ involvement (bone marrow, liver, spleen) associated with poor prognosis ([Am J Hematol 2024;99:871](38409747))* Median overall survival of multifocal / disseminated disease is < 1 year compared to unifocal / localized disease with median overall survival of > 2 years ([Am J Hematol 2024;99:871](38409747), [Ann Hematol 2019;98:2641](31741033))* Mortality rates are similar in isolated nodal or extranodal involvement with a 1 year mortality rate estimated at ~20 - 30%; however, combined nodal and extranodal sites have an estimated 1 year mortality rate at ~78% ([Ann Hematol 2019;98:2641](31741033))* Surgically resectable disease has a 1 year mortality rate of ~18% compared to nonresectable disease with 63% ([Ann Hematol 2019;98:2641](31741033))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-12",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#casereports519016",
    "clean_content": "Case reports\n\n* 38 year old woman with painless right breast mass and bilateral neck masses ([Virchow Arch 2005;446:546](15806378))* 59 year old man with positron emission tomography (PET) avid left axillary lymphadenopathy ([Cancer Biol Ther 2015;16:1128](26047060))* 81 year old woman with asymptomatic skin papule in left temporal region ([Pathol Res Pract 2023;247:154559](37210770))* 81 year old man with history of gradually progressive painless mass in right submandibular region ([Head Neck Pathol 2016;10:145](25893828))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-13",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#treatment519017",
    "clean_content": "Treatment\n\n* Unifocal / localized disease can be treated with surgical resection, with some cases achieving complete remission ([Am J Hematol 2024;99:871](38409747))* Variable response to radiation therapy ([Am J Hematol 2024;99:871](38409747), [Ann Hematol 2019;98:2641](31741033))* Chemotherapy regimens or targeted therapy with MEK / BRAF inhibitors in those with MAPK alterations have shown limited efficacy without durable responses ([Am J Hematol 2024;99:871](38409747))* Immune checkpoint inhibitors have been attempted in cases with high PDL1 expression ([Am J Hematol 2024;99:871](38409747))"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-14",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#grossdescription519019",
    "clean_content": "Gross description\n\n* Usually circumscribed with vaguely lobulated appearance and fleshy cut surface"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-15",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#microscopichistologicdescription519023",
    "clean_content": "Microscopic (histologic) description\n\n* Pleomorphic spindled or epithelioid cells arranged in fascicles, whorls or sheet-like patterns, often with indistinct cell borders and are characterized by large nuclei, vesicular chromatin, distinct nucleoli and abundant eosinophilic cytoplasm ([Am J Clin Pathol 2001;115:589](11293908))* Paracortical distribution or diffuse effacement in lymph nodes* Occasional multinucleated forms may be present* Variable degree of admixed inflammatory cells, primarily lymphocytes and plasma cells"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-16",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#microscopichistologicimages519024",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Aishwarya Ravindran, M.D. and Karen L. Rech, M.D.  \n\n[![Epithelioid tumor cells with indistinct cell borders](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech01.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech01.jpg)\nâ€ƒ\n[![Epithelioid tumor cells with indistinct cell borders](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech02.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech02.jpg)\n\nEpithelioid tumor cells with indistinct cell borders\n\n[![CD68](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech_03.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech_03.jpg)\n\nCD68\n\n[![CD163](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech04.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech04.jpg)\n\nCD163\n\n  \n\n[![CD14](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech05.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech05.jpg)\n\nCD14\n\n[![S100](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech06.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech06.jpg)\n\nS100\n\n[![Cyclin D1](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech07.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech07.jpg)\n\nCyclin D1\n\n[![OCT2](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech08.jpg)](https://www.pathologyoutlines.com/imgau/lymphnodesinterdigitatingreticulumravindranrech08.jpg)\n\nOCT2"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-17",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#positivestains519030",
    "clean_content": "Positive stains\n\n* 2 lineage subsets ([Mod Pathol 2023;36:100268](37406859))\n  + Macrophage - monocyte phenotype: [S100](https://www.pathologyoutlines.com/topic/stainss100.html) (diffuse), [CD4](https://www.pathologyoutlines.com/topic/cdmarkerscd4.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [CD14](https://www.pathologyoutlines.com/topic/cdmarkerscd10to19.html#cd14), [OCT2](https://www.pathologyoutlines.com/topic/stainsOCT2.html)+ Classical dendritic cell phenotype: [S100](https://www.pathologyoutlines.com/topic/stainss100.html) (diffuse), [CD4](https://www.pathologyoutlines.com/topic/cdmarkerscd4.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html) (majority show golgi / dot-like pattern of staining), [CD11c](https://www.pathologyoutlines.com/topic/cdmarkerscd10to19.html#cd11c), **ZBTB46**\n      - This subset may be better classified as dendritic cell sarcoma, NOS* [Cyclin D1](https://www.pathologyoutlines.com/topic/stainscyclind1.html) is expressed reflecting MAPK pathway activation"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-18",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#negativestains519031",
    "clean_content": "Negative stains\n\n* Follicular dendritic cell markers: [CD21](https://www.pathologyoutlines.com/topic/cdmarkerscd21.html), [CD23](https://www.pathologyoutlines.com/topic/cdmarkerscd23.html), [CD35](https://www.pathologyoutlines.com/topic/cdmarkerscd30to39.html#cd35), **clusterin**, [CXCL13](https://www.pathologyoutlines.com/topic/stainsCXCL13.html)* Langerhans cell markers: [CD1a](https://www.pathologyoutlines.com/topic/cdmarkerscd1a.html), [langerin](https://www.pathologyoutlines.com/topic/cdmarkerscd200.html#cd207)* Mesenchymal markers: [actin](https://www.pathologyoutlines.com/topic/stainsactin.html), [desmin](https://www.pathologyoutlines.com/topic/stainsdesmin.html), [CD31](https://www.pathologyoutlines.com/topic/cdmarkerscd31.html), [CD34](https://www.pathologyoutlines.com/topic/cdmarkerscd34.html)* Epithelial markers: [EMA](https://www.pathologyoutlines.com/topic/stainsema.html), [keratin](https://www.pathologyoutlines.com/topic/stainsckgeneral.html) ([AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html), [CAM5.2](https://www.pathologyoutlines.com/topic/stainscam52.html))* Melanoma markers: [HMB45](https://www.pathologyoutlines.com/topic/stainshmb45.html), [MelanA](https://www.pathologyoutlines.com/topic/stainsmart1.html), [SOX10](https://www.pathologyoutlines.com/topic/stainssox10.html)* Lymphoma markers: [CD3](https://www.pathologyoutlines.com/topic/cdmarkerscd3.html), [CD20](https://www.pathologyoutlines.com/topic/cdmarkerscd20.html), [CD30](https://www.pathologyoutlines.com/topic/cdmarkerscd30.html)* References: [Mod Pathol 2023;36:100268](37406859), [Am J Surg Pathol 2004;28:988](15252304)"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-19",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Electron microscopy description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#electronmicroscopydescription519034",
    "clean_content": "Electron microscopy description\n\n* Interdigitating cytoplasmic processes but no desmosomes or other junctional complexes, no Birbeck granules"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-20",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#molecularcytogeneticsdescription519036",
    "clean_content": "Molecular / cytogenetics description\n\n* MAPK pathway alterations, including mutations in *BRAF* V600E, *KRAS* and *NRAS* genes are frequent ([Oncologist 2021;26:e1263](33904632), [Mod Pathol 2023;36:100268](37406859))* In the setting of prior B / T cell neoplasms, shared genetic features between lymphoma and interdigitating dendritic cell sarcoma (IDCS) are present, such as *IGH::BCL2* fusion in IDCS associated with follicular lymphoma ([Mod Pathol 2023;36:100268](37406859))* Positive clonal B cell immunoglobulin gene rearrangement or T cell receptor gene rearrangement in secondary IDCS associated with prior B cell or T cell neoplasm"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-21",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#samplepathologyreport519039",
    "clean_content": "Sample pathology report\n\n* Lymph node, left neck, excisional biopsy:\n  + Interdigitating dendritic cell sarcoma (see comment)+ Comment: The submitted histologic sections show a portion of lymph node with a nodal architecture effaced by sheets of atypical epithelioid to spindled shaped cells. These neoplastic cells have large ovoid to folded nuclei with variable degrees of nuclear pleomorphism, vesicular chromatin, multiple small nucleoli and abundant pale eosinophilic cytoplasm.+ Immunostains were performed on formalin fixed and paraffin embedded tissue sections of the left neck lymph node (CD3, CD20, CD14, CD68, CD163, PU.1, CD1a, langerin, keratin (AE1 / AE3), SOX10, MelanA, HMB45, S100, OCT2, CD11c, CD21, CD23). The abnormal cells are positive for histiocytic markers (CD14, CD68, CD163, PU.1, OCT2), CD11c and S100 (diffuse and strong). The neoplastic cells are negative for melanocytic markers (SOX10, MelanA, HMB45), Langerhans cell markers (CD1a, langerin) and other markers tested. The overall morphologic and immunophenotypic findings support the diagnosis of interdigitating dendritic cell sarcoma."
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-22",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#differentialdiagnosis519040",
    "clean_content": "Differential diagnosis\n\n* [Histiocytic sarcoma (HS)](https://www.pathologyoutlines.com/topic/lymphnodeshistiocyticsarcoma.html):\n  + Histologically indistinguishable from interdigitating dendritic cell sarcoma (IDCS)+ Macrophage phenotype; may show focal [S100](https://www.pathologyoutlines.com/topic/stainss100.html) expression, unlike the strong uniform expression in IDCS ([Mod Pathol 2023;36:100268](37406859))* [Langerhans cell sarcoma (LCS)](https://www.pathologyoutlines.com/topic/lymphnodesLCH.html):\n    + Histologically indistinguishable from IDCS+ Positive for [CD1a](https://www.pathologyoutlines.com/topic/cdmarkerscd1a.html) and **langerin*** [Follicular dendritic cell sarcoma (FDCS)](https://www.pathologyoutlines.com/topic/lymphnodesFDCsarcoma.html):\n      + Histologically may have overlapping features with IDCS+ Positive for FDC markers ([CD21](https://www.pathologyoutlines.com/topic/cdmarkerscd21.html), [CD23](https://www.pathologyoutlines.com/topic/cdmarkerscd23.html), [CD35](https://www.pathologyoutlines.com/topic/cdmarkerscd30to39.html#cd35), **clusterin**, [CXCL13](https://www.pathologyoutlines.com/topic/stainsCXCL13.html)) ([Am J Surg Pathol 2004;28:988](15252304))+ Negative for hematolymphoid markers ([CD45](https://www.pathologyoutlines.com/topic/cdmarkerscd45.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html))* [Metastatic melanoma](https://www.pathologyoutlines.com/topic/skintumormelanocyticmetastaticmelanoma.html):\n        + Histologically may have overlapping features with IDCS; cytoplasm may contain brown pigment (melanin)+ Positive for [S100](https://www.pathologyoutlines.com/topic/stainss100.html), [Melan A](https://www.pathologyoutlines.com/topic/stainsmart1.html), [SOX10](https://www.pathologyoutlines.com/topic/stainssox10.html)+ Negative for hematolymphoid markers ([CD45](https://www.pathologyoutlines.com/topic/cdmarkerscd45.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html))* [Diffuse large B cell lymphoma](https://www.pathologyoutlines.com/topic/lymphomadiffuse.html):\n          + Histologically may be similar with large discohesive cells+ Positive for [CD20](https://www.pathologyoutlines.com/topic/cdmarkerscd20.html), [CD45](https://www.pathologyoutlines.com/topic/cdmarkerscd45.html), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html)+ Negative for [S100](https://www.pathologyoutlines.com/topic/stainss100.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163)* [Anaplastic large cell lymphoma](https://www.pathologyoutlines.com/topic/lymphomanonBanaplasticneg.html):\n            + Large anaplastic cells with abundant eosinophilic cytoplasm+ Positive for [CD30](https://www.pathologyoutlines.com/topic/cdmarkerscd30.html); variable positivity for [CD45](https://www.pathologyoutlines.com/topic/cdmarkerscd45.html), [CD2](https://www.pathologyoutlines.com/topic/cdmarkerscd1.html#cd2), [CD3](https://www.pathologyoutlines.com/topic/cdmarkerscd3.html), [CD4](https://www.pathologyoutlines.com/topic/cdmarkerscd4.html), [CD5](https://www.pathologyoutlines.com/topic/cdmarkerscd5.html), [CD7](https://www.pathologyoutlines.com/topic/cdmarkerscd1.html#cd7)+ Negative for [S100](https://www.pathologyoutlines.com/topic/stainss100.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html)* [Metastatic carcinoma](https://www.pathologyoutlines.com/topic/lymphnodesmetastases.html):\n              + Usually epithelioid cells in sheets, clusters or single cells+ Positive for [keratin](https://www.pathologyoutlines.com/topic/stainsckgeneral.html) ([AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html))+ Negative for hematolymphoid markers ([CD45](https://www.pathologyoutlines.com/topic/cdmarkerscd45.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html))* [Pleomorphic sarcoma](https://www.pathologyoutlines.com/topic/softtissuemfhpleo.html):\n                + Pleomorphic cells with a spectrum of cytology and may include spindled, plasmacytoid, epithelioid or multinucleated forms+ Tumor cells are negative for histiocytic markers ([CD4](https://www.pathologyoutlines.com/topic/cdmarkerscd4.html), [CD68](https://www.pathologyoutlines.com/topic/cdmarkerscd68.html), [CD163](https://www.pathologyoutlines.com/topic/cdmarkerscd160.html#cd163), [PU.1](https://www.pathologyoutlines.com/topic/stainspu1.html)); caution should be used to not misinterpret admixed reactive histiocytes"
  },
  {
    "id": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt-23",
    "source_document": "interdigitating-dendritic-cell--reticulum-cell-sarcoma_48219_1750165658.txt",
    "parent": "lymph-nodes--spleen-nonlymphoma_41",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html#additionalreferences522443",
    "clean_content": "Additional references\n\n* [WHO Classification of Tumours Editorial Board: Haematolymphoid Tumours, 5th Edition, 2024](https://www.amazon.com/exec/obidos/ASIN/9283245202/pathologyoutl-20)"
  }
]